Clinical Trials Logo
  1. Home
  2. Type 2 Diabetic Patients
  3. NCT01049321
  4. Details
NCT01049321 Clinical Trial

The Effect of DASH Diet on the Cardiometabolic Risks and Hepatic Function Among Type 2 Diabetic Patients

Type 2 Diabetic Patients Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01049321
Other study ID # DASH and cardiovascular risks
Secondary ID
Status Completed
Phase Phase 4
First received January 13, 2010
Last updated January 13, 2010
Start date December 2008
Est. completion date December 2009

Study information
Verified date March 2008
Source Isfahan University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority Iran: Isfahan University of Medical Sciences
Study type Interventional

Clinical Trial Summary

The investigators are not aware of any study regarding the effect of DASH eating pattern on different cardiovascular risks among type 2 diabetic patients. The investigators assumed that DASH eating pattern could reduce the cardio-metabolic risks and improve the hepatic function among type 2 diabetes.

Recruitment information / eligibility
Status Completed
Enrollment 36
Est. completion date December 2009
Est. primary completion date June 2009
Accepts healthy volunteers No
Gender Both
Age group 44 Years to 70 Years
Eligibility Inclusion Criteria:

- Having type 2 diabetes

Exclusion Criteria:

- Having other chronic disease, hepatic or kidney disorders, cancer, hormone therapy

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Dietary Supplement:
• DASH diet

• a usual diabetic diet

Locations
Country Name City State
Iran, Islamic Republic of Shahid motahari hospital, Esfahan Esteel company, Iran Isfahan

Sponsors (2)
Lead Sponsor Collaborator
Isfahan University of Medical Sciences Shahid Motahari Hospital of Fooladshahr, Isfahan Steel Company, Isfahan

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Cardio-metabolic risks 6 months Yes
Secondary Hepatic function 6 months Yes
See also
  Status Clinical Trial Phase
Completed NCT03006159 - A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients Phase 1
Completed NCT01049750 - Prevalence and Risk Factors of Erectile Dysfunction in Type 2 Diabetic Patients N/A
Not yet recruiting NCT03987308 - Comparing the Efficacy and Safety Between Short-term Continuous Subcutaneous Beinaglutide Injection and Continuous Subcutaneous Insulin Infusion (CSII) for Newly Diagnosed Type 2 Diabetes N/A
Completed NCT02164578 - Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk Phase 3
Completed NCT00941148 - Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin Phase 4